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A B S T R A C T
Despite continuing improvements in multimodal therapies, gastro-esophageal malignances remain widely pre-
valent in the population and is characterized by poor overall and disease-free survival rates. Due to the lack of
understanding about the pathogenesis and absence of reliable markers, gastro-esophageal cancers are associated
with delayed diagnosis. The increasing understanding about cancer's molecular landscape in the recent years,
oﬀers the possibility of identifying ‘targetable’ molecular events and in particular facilitates novel treatment
strategies and development of biomarkers for early stage diagnosis. At least 98% of our genome is actively
transcribed into non-coding RNAs encompassing long non-coding RNAs (lncRNAs) constituted of transcripts
longer than 200 nucleotides with no protein-coding capacity. Many studies have demonstrated that lncRNAs are
functional genomic elements playing pivotal roles in main oncogenic processes. LncRNA can act at multiple
levels developing a complex molecular network that can modulate directly or indirectly the expression of genes
involved in tumorigenesis. In this review, we focus on lncRNAs as emerging players in gastro-esophageal car-
cinogenesis and critically assess their potential as reliable noninvasive biomarkers and in next generation tar-
geted therapies.
1. Introduction
Less than 2% of the human genome consists of protein-coding genes,
and at least 98% of our genome is actively transcribed into non-coding
RNAs (ncRNAs), which were previously regarded as transcriptional
“noise” or “junk” [1]. NcRNAs is a broad umbrella term that includes
long non-coding RNAs (lncRNAs) in addition to pseudogenes, telomeric
repeat-containing RNAs (TERRAs), transcribed ultra-conserved regions
(T-UCRs), enhancer RNAs (eRNAs), circular RNAs (circRNAs), micro-
RNAs (miRNAs) and piwi-RNA (piRNAs) [2–5]. LncRNAs in essence
codes for RNA transcripts longer than 200 nucleotides with no protein-
coding capacity [6]. Intriguingly, in contrast with this deﬁnition some
of them could be translate into short (∼40AA) nonfunctional peptides
[7], so should be better to talk of no/little protein coding capacity.
Their present estimated number in the human genome is about 167,000
and it is expected to increase further [8].
LncRNAs are transcribed by RNA polymerase II/III, show epigenetic
features common to protein-coding genes, such as trimethylation of
histone 3 lysine 4 at the transcriptional start site and trimethylation of
histone 3 lysine 36 throughout the gene body and are commonly sub-
jected to splicing [9]. Many studies have demonstrated that lncRNAs
are functional genomic elements, and exhibit proximity to disease-as-
sociated genomic polymorphisms, and cancer-speciﬁcity [10]. The
dysregulation of lncRNA has been extensively reported in the context of
carcinogenesis and metastasis.
In this present review, we will focus on lncRNAs as novel and
emerging players in the wide ﬁeld of gastro-esophageal carcinogenesis,
concentrating on their working mechanism and subsequent
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implications for diagnosis, follow-up and treatment.
2. Biology of LNCRNAs
Despite the multiple emerging functions exerted by lncRNAs, sev-
eral aspects pertaining to structural functionality and biological re-
levance of lncRNAs remain unclear. Additionally, in contrast to mRNAs
and proteins, the function of lncRNA cannot simply be described ac-
cording to their structure sequence because of their inherent complexity
and diversity [11–13]. LncRNAs exhibit high evolutionary conserva-
tion, actively regulated promoters, a speciﬁed length (from 200 to
100,000 nucleotides), can be either polyadenylated or non-poly-
adenylated, undergo alternative splicing, tend to have a low sequence
identity (nucleic acid sequence of ∼50–60%) and a low abundance
(their median expression levels are ∼10 times lower than those of
mRNAs) [10,14,15]. Another important element of lncRNAs is their
high tissue-speciﬁcity, particularly linked to their carcinogenic eﬀect
[15].
From the genetic point of view, the lncRNAs can be categorized as:
(i) promoter-associated: non-coding transcripts deriving from the pro-
moter region; (ii) sense oriented: lncRNAs and mRNAs are present on
the same strand, with some overlapping exons; (iii) antisense oriented:
lncRNAs and mRNAs are present on the same strand on the opposite
chain, with at least one exon overlapping; (iv) bidirectional: the tran-
scription start site of the lncRNA and its adjacent gene are on the an-
tisense strand; (v) intronic: lncRNAs that begin their transcription in-
side an intron of protein-coding gene without overlapping exons; (vi)
intergenic: lncRNAs that lies within the genomic interval between two
protein-coding genes, as a separate unit; (vii) 3′UTR-associated tran-
scripts: lncRNAs overlapping 3′UTR region; (viii) 5′UTR-associated
transcripts: lncRNAs overlapping 5′UTR region [16–19].
The above described location-based classiﬁcation tries to capture a
snapshot of the contemporary biological knowledge and it could rapidly
evolve to include functional attributes in accordance with novel in-
sights and discoveries.
Mechanistically, lncRNAs can control the timing and degree of gene
expression by acting both in cis- (local control of genes neighboring)
and trans- (control of distant genes) regulation at diﬀerent levels: (i)
epigenetic modiﬁcations: reversible and heritable changes in gene ex-
pression in the absence of a change in the DNA sequence; this mod-
iﬁcations include recruitment of chromatin remodeling complexes to
speciﬁc genomic loci, methylation of DNA and histone acetylation; (ii)
transcriptional regulations: promoters and transcription factors activity
modulation; (iii) post-transcriptional regulations: lncRNAs can inﬂu-
ence mRNA alternative splicing, or can act as competing endogenous
RNAs (ceRNAs) serving as molecular sponges for miRNAs or can par-
ticipate in the post-translational modiﬁcations of proteins; (iv) other
mechanisms encompass the association with other lncRNAs; (v) ﬁnally,
they might be also aﬀected by single-nucleotide polymorphisms (SNPs)
[20]. Fig. 1 summarized these biological knowledges.
3. LNCRNAs in esophageal cancer
Esophageal cancer (EC) is the sixth leading cause of cancer-related
deaths worldwide [21] and has two major histotypes: squamous cell
carcinoma (ESCC) and adenocarcinoma (EAC). EC has a poor prognosis:
the overall 5-year survival of stage III is about 10–15% and the median
survival time of stage IV is less than 1 year [22]. Given this unfavorable
prognosis, many recent studies have focused on novel therapeutic tar-
gets, including lncRNAs. Table 1 summarized and integrate these stu-
dies.
3.1. LncRNAs involved in ESCC
3.1.1. Upregulated lncRNAs
− MALAT1 (Metastasis associated lung adenocarcinoma transcript 1;
also known as NEAT2: nuclear-enriched abundant transcript 2) is a
nuclear lncRNA, located in the chromosome 11q13, initially re-
ported to be overexpressed in invasive non-small cell lung carci-
noma (NSCLC) and acting as an oncogene [23,24]. MALAT1 is
strongly conserved among mammals and is widely expressed in
human kidney, heart, brain and spleen [25]. MALAT1 locus tran-
scripts are of 2 types: one 6700 bp nucleic (MALAT1) and the other
being 61 bp cytoplasmic MALAT1-associated small cytoplasmic RNA
(mascRNA) [26]. Wang et al. focused on the interaction between
miR-101, miR-217 and MALAT1, demonstrating how this lncRNA
can act as a competing endogenous RNAs (ceRNA) sequestering
these two miRNAs. MiR-101, miR-217 are involved in regulation of
cell cycle; particularly, they inhibit cell cycle by G2/M transition
arrest, block cell migration and invasion. Indeed, ESCC tissues
showed very high levels of MALAT1 and, conversely, a down-reg-
ulation of miR-101 and miR-217 compared to adjacent non-can-
cerous tissues [27]. Based on previous studies, authors paid atten-
tion to one of the most activated pathways in cancer: the Wnt/β-
catenin one, which is upregulated in ESCC too. The enhancer of
zeste homolog 2 (EZH2) expression was found signiﬁcantly higher in
ESCC tissue than in normal one. A tested down-regulation of
MALAT1 inhibited the expression of EZH2 from mRNA to protein.
Therefore, it was proved MALAT1 expression increases the Wnt/β-
catenin pathway, via EZH2 [28]. EZH2 is the catalytic subunit of
polycomb-group (PcG) proteins complex-2 (PCR2); this complex has
histone methyltransferase activity and can epigenetically regulate
gene expression. Finally, the same article focused on the prognostic
impact of MALAT1 in ESCC. Its expression is associated with stage,
lymph-nodes metastasis and to poor overall survival (OS) [28].
These studies conﬁrm the oncogenetic role of MALAT1 in ESCC.
− HOTAIR (HOX Transcript Antisense RNA) is a transcript of ∼2200
bp, located on chromosome 12, initially linked to primary and
metastatic breast tumor [29,30]. In ESCC, it is known as an in-
dependent prognostic indicator; in fact, its expression is correlated
to stage and lymph node metastasis [31]. Ge et al. studies showed an
epigenetic activity of HOTAIR in regulating the Wnt/β-catenin sig-
naling pathway. Precisely, HOTAIR with its 5′ domain binds to
polycomb repressive complex 2 (PRC2), and its 3′ domain binds the
LSD1/CoREST/REST complex, coordinating PRC2 and LSD1 to
target chromatin, leading to the methylation of histone H3 lysine 27
(H3k27) and to the demethylation of lysine 4 (H3K4), respectively.
This chromatin remodeling involves the promoter region of the gene
Wnt inhibitory factor-1 (WIF-1) which consequently arrests its ex-
pression with the upregulation of Wnt/β-catenin signaling pathway.
The eﬀects include translocation of β-catenin in the cell nucleus,
exerting its transcriptional activity, and the consequent expression
of related genes, such as c-Myc and Cyclin D1, which control the G1
to S phase transition in cancer cells [30,32,33]. In addition, a recent
genetic study identiﬁed a higher risk of developing ESCC in
rs920778 TT carriers in HOTAIR gene compared rs920778CC car-
riers. This allelic regulation clearly demonstrates the key role of
HOTAIR in ESCC developing and progression [34].
− ANRIL (Antisense ncRNA in the INK4 locus; also known as CDKN2B-
AS1: Cyclin-dependent kinase 4 inhibitor B - antisense RNA 1) is a
3.8 kb lncRNA located within the CDKN2B-CDKN2A gene cluster at
chromosome 9p21 [35]. This locus is homozygously deleted or si-
lenced in cardiovascular diseases, type 2 diabetes and several types
of cancers with a frequency of 30–40%, becoming one of the most
frequently altered genes in human malignancies [36–38]. It is
overexpressed in gastric cancer (GC) [38], and ESCC [39]. ANRIL
silencing blocks cancer cells proliferation in G0-G1 phase and
G.N. Fanelli et al. Non-coding RNA Research 3 (2018) 195–212
196
induces cell apoptosis both in vitro and in vivo. ANRIL transcription
is induced by ATM-E2F1 signaling pathway [40,41] and acts as an
oncogene bot in cis and in trans. Indeed, in cis it can recruit and bind
to PRC2 (at its RNA binding domain in subunit: SUZ12) inducing
methylation of H3K27 and consequently silencing p15INK4B, which is
a tumor suppressor gene [40]; ANRIL can also bind to PRC1 (at its
RNA binding domain in subunit: CBX7) silencing the p16INK4A/
p14ARF, another important tumor suppressor gene. Furthermore, in
trans, by the recruitment of PCR2, it can epigenetically repress the
transcription of miR-99a/miR-449a. The well-known targets in-
hibited by miR-99a/miR-449a are CDK6 and mTOR, both important
positive modulators of cell cycle progression. Since p15INK4B and
p16INK4A are also inhibitors of CDK6 and mTOR, together this leads
to a signiﬁcant increase expression of CDK6, mTOR, and in a de-
phosphorylation of RB protein resulting in an overexpression of
E2F1 that consequently induces ANRIL expression. In this way, it
establishes a positive feedback loop that induces cell cycle dereg-
ulation and promotes cancer cells proliferation [38,39]. These re-
sults suggest that ANRIL could be a good candidate prognostic
biomarker and target for new target therapy.
− H19. This lncRNA can act as either an oncogene or a tumor sup-
pressor gene depending on cancer types. It was initially reported to
be upregulated in human breast tumors [42,43]. Also in ESCC pa-
tients, a signiﬁcant upregulation of H19 has been reported; more-
over, its level is correlated with higher depth of invasion, neoplastic
grading and TNM [44,45]. The functional mechanism of this lncRNA
will be further analyzed in the GC section.
− POU3F3 (lnc-POU Class 3 Transcription Factor 3) is located in the
chromosome 2q12, near the POU3F3 gene. Li et al. demonstrated a
signiﬁcant overexpression of this lncRNA in ESCC tissues and in vitro
this gives a greater ability to form colonies and an up-regulation of
the proliferation. An overexpression of lnc-POU3F3 induces the
methylation of POU3F3 promoter via EZH2, a key component of
PCR2. The main targets of PRC2 are signaling components and
transcription factors like the POU transcription factor families. So
ﬁrst, they concluded that there is a connection between lncPOU3F3
and POU3F3 protein, via EZH2 protein. Second, they hypothesized
that the conserved-DNA position of lncPOU3F3 is functionally
linked to PcG proteins in order to regulate neighbor genes expres-
sion altering their methylation [46].
− TUG1 (Taurine up-regulated lncRNA) was ﬁrst identiﬁed in the
diﬀerentiation process of retinal cells [47]. In 2014 Zhang et al. [48]
found that in NSCLC, the expression of TUG1 was signiﬁcantly
down-regulated compared with the normal controls, and its ex-
pression was signiﬁcantly correlated with TNM stage, tumor size
and poorer OS. However, in contrast with this discovery, Xu et al.
[49] demonstrated an overexpression of TUG1 in ESCC compared
with adjacent normal tissue; in addition, the same paper provided
clear evidences that silencing TUG1 is possible to inhibit prolifera-
tion, migration, and cell cycle. Although the TUG1 molecular me-
chanism of action is not well elucidated it has been demonstrated
that it is activated by p53 and can bind the methylated and un-
methylated PRC2 together with MALAT1, regulating homeobox B7
(HOXB7) expression by interacting with EZH2 [50,51]. Regardless,
this diﬀerent behavior may indicate a bifunctional nature of the
lncRNA or may be due to the diﬀerences of cellular context.
− SOX2-OT (SOX2 overlapping transcript) is located in the 3q26.33
locus and has been demonstrated playing a pivotal role in vertebrate
development [52]. SOX2-OT locus overlap, on the third intron, to
the single-exon gene SOX2, an important transcriptional factor, that
act as pluripotency state modulator. Recently Shahryari et al.
[53,54] found an overexpression of SOX2-OT in paired human
Fig. 1. LncRNAs biogenesis and biological acting mechanisms.
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tumor/non-tumor samples of ESCC and in NTERA2, a human em-
bryonal carcinoma stem cell line. In addition, they found that SOX2
was co-upregulated in tumor samples and the silencing of SOX2-OT
deregulates cell cycle. Finally, in ESCC, two novel SOX2-OT spliced
variants (SOX2OT-S1 and SOX2OT-S2) were found to be dysregu-
lated and participate in tumor initiation and progression [53]. All of
these evidences suggested that SOX2-OT can mutually act with
SOX2 and can modulate cancer stemness, but the underlying me-
chanism of the overexpression of SOX2-OT in ESCC remains to be
further discussed.
− UCA1 (Urothelial cancer-associated 1; also known as CUDR: Cancer
Upregulated Drug Resistant) is located in 19p13.12 locus and con-
tains three exons encoding two transcripts, one of 1200 bp in length,
and other of 2.2 bp; was ﬁrstly found upregulated in bladder cancer
[55,56] and later in breast cancer [57], tongue squamous cell car-
cinomas [58], colorectal cancer [59], and ESCC [60]. Jiao et al. [61]
showed that UCA1 can compete with SOX4 mRNA for miR-204, an
important tumor suppressor miRNA in various cancers, this reduces
the binding of miR-204 to SOX4 3′UTR and thereby the miR-204-
mediated inhibition of SOX4 is reduced. SOX4 protein is a member
of the Sry-related high mobility group box (SOX) family transcrip-
tion factors and it is involved in apoptosis as well as tumorigenesis
and cancer stemness. Other UCA1 downstream targets include cAMP
response element-binding protein (CREB) [62], p27 (Kip1) [57] and
hexokinase 2 (HK2) [60] that modulate a variety of cellular pro-
cesses including cell cycle and glycolysis. UCA1 silencing results in
decreased cell proliferation, migration and invasion ability; whereas
higher UCA1 expression correlated with poor diﬀerentiation, ad-
vanced clinical stage and a poorer prognosis [63].
− CBR3-AS1 (Carbonyl Reductase 3 antisense RNA 1; also known as
PlncRNA-1: Prostate Cancer Up-Regulated Long Noncoding RNA 1)
is located on chromosome 21 and was found signiﬁcantly over-
expressed in prostate cancer compared with normal tissues and
benign prostatic hyperplasia (BPH). Silencing CBR3-AS1 through
the down-expression of androgen receptor mRNA and protein as
well as androgen receptor downstream targets, blocks proliferation
and induces apoptosis in prostate cancer cell lines [64]. CBR3-AS1
level is signiﬁcantly higher in human ESCC than in normal tissue
and is related with advanced clinical stage, lymph node metastasis;
whereas knockdown of CBR3-AS1 could prevent cell proliferation,
induce cell apoptosis and promote cycle transit from G1 to S phase
[65]. However, the underlying mechanism of PlncrNA-1 function in
ESCC remains unknown.
− FOXCUT (LncRNA Fork head box C1 Upstream Transcript) and its
adjacent FOXC1 gene are overexpressed in both oral squamous cell
carcinoma and ESCC [66,67]. Remarkably, upregulated FOXCUT
and FOXC1 expression levels are correlated with poor diﬀerentia-
tion, lymph node metastasis and worse prognosis [67]. FOXCUT
silencing reduces cell proliferation, migration, invasion and colony
formation and the expression of FOXC1 gene, so FOXCUT might
modulate FOXC1 mRNA synthesis [68]. However, the mechanism of
how FOXCUT interacts with FOXC1 to regulate the ESCC progres-
sion is still unclear.
− SPRY4-IT1 (Sprouty 4 intronic transcript 1) is a 708 bp lncRNA
located on chromosome 5 and transcribed from the second intron of
SPRY4 gene [69]. It is highly expressed in melanoma cells, tro-
phoblast cells, clear cell renal cell carcinoma, and ESCC [70–73] and
downregulated in NSCLC cancer [74]. In vitro studies demonstrated
that SPRY4-IT1 is upregulated in cancer cells, where it is able to
increase motility, promote vimentin, ﬁbronectin and SNAIL genes
expression; and also a concomitant decrease of E-Cadherin gene
expression in order to support the epithelial-mesenchymal transition
(EMT), a critical process for tumor metastasis [75,76]. Furthermore,
high expression of SPRY4-IT1 is associated with tumor diﬀerentia-
tion, lymph node metastasis and clinical stage rather than patient's
gender, smoking status, alcohol consumption and tumor location
[77]. These results conﬁrm that SPRY4-IT1 can act as an oncogenic-
regulator in ESCC [78].
− CCAT 2 (Colon cancer associated transcript 2), mapped to 8q24.21,
is another important lncRNA involved in ESSC tumorigenesis. Its
DNA locus is essential, because of its proximity to MYC gene, about
335 kb away, and is often ampliﬁed in ESCC. Zhang et al. in-
vestigated that MYC and CCAT2 ampliﬁcation occur simultaneously.
MYC overexpression, and consequently CCAT2, induced chromo-
somal instability and altered DNA replication Since CCAT2 ampli-
ﬁcation is related to worse clinical outcome (advanced TNM stages
and number of metastatic lymph nodes), it has been argued as a
prognostic factor in ESCC [79].
− CASC9 (Cancer susceptibility candidate 9), mapped to 8q21.11, is a
lncRNA highly expressed in ESCC compared to adjacent normal
tissue. Particularly, its expression is higher in poor diﬀerentiated
carcinomas.CASC9 in vitro inhibition causes an arrest of cell mi-
gration and invasion [80].
− CCAT1 (Colon cancer-associated transcript-1; also known as
LncRNA CARLo-5) is located at an intergenic region on chromosome
8 and was ﬁrst identiﬁed in colorectal cancer [81]. It is upregulated
in ESCC and can recruit EZH2 and SUV39H1; this leads to the epi-
genetic downregulation of SPRY4, an important tumor suppressor
gene [82].
− PCAT-1 (Prostate cancer-associated ncRNA transcript 1) is located in
8q30 and is about 725 kb upstream of the c-Myc oncogene. PCAT-1
interacts with PRC2 and regulate H3K27 methylation [83]. A high
expression of PCAT-1 was found in human ESCC and was associated
with invasion, lymph node metastasis, advanced pathologic stage
and a shorter OS. Therefore, PCAT-1 may be used as a potential
diagnostic signature to evaluate ESCC patients prognosis [84].
− PEG10 (lcnRNA Paternally Expressed Gene 10) is a 763 bp long
transcript located in chromosome 7. It has been found overexpressed
in EC tissues and related to lymph node metastasis. PEG10 silencing
inhibits proliferation and invasion and enhance apoptosis in EC cell
lines [85]. However, PEG10 role in ESCC remains to be elucidated.
3.1.2. Downregulated lncRNAs
− TUSC7 (Tumor suppressor candidate 7; also known as LSAMP-AS3:
LSAMP antisense RNA3 or as lncRNA LOC285194) is a newly
identiﬁed lncRNA, comprising 4 exons with a length of about 2100
bp and is situated at 3q13.31 locus. TUSC7 is activated by p53 and
there is also a mutually repressive interaction between TUSC7 and
miR-23b and miR-211 [86,87]. TUSC7 plays a key role in cell
growth inhibition through the suppression of miR-23b in GC, colon
cancer and osteosarcoma [88]. According to these ﬁndings, Tong
et al. [86] recently have shown that TUSC7 is downregulated also in
ESCC is and can act as a tumor suppressor gene. Moreover, is as-
sociated with chemo-radiotherapy resistance; in fact, among pa-
tients treated with neoadjuvant chemo-radiotherapy followed by
surgical resection, the rate of pathological complete regression
grade was higher in patients with high TUSC7 expression.
− LOC100130476 is located on 6q23.3 and contains 3 CpG islands.
Recent studies investigate, its role in ESCC [89] and gastric cardia
adenocarcinoma (GCA) [90], focusing on the importance of its
methylation status. In both studies LOC100130476 is signiﬁcantly
downregulated due to hypermethylation of the CpG sites in exon 1,
which is close to the transcription starting site. Conversely, over-
expression of LOC100130476 in ESCC cell lines inhibits cell pro-
liferation and reduces invasiveness. Therefore, these results re-
cognize the lncRNA LOC100130476 as a tumor suppressor in ESCC
and in GCA.
3.1.3. Other ESCC-related lncRNAs
LincRNA-uc003opf.1 (Long Intergenic Non-Protein Coding RNA
951) is mapped on chromosome 3. Wu et al. in a Chinese population-
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based study, found the presence of the SNP rs11752942A > G in the
exon of this lncRNA. The rs11752942 GG and AG genotypes had a
markedly decreased risk of ESCC, compared with the rs11752842AA
genotype. The rs11752942G allele could markedly attenuate the level
of lincRNA-uc003opf.1 both in vivo and in vitro by binding micro-RNA-
149, reducing cell proliferation and tumor growth. Therefore, genetic
polymorphism rs11752942A > G in lincRNA-uc003opf.1 exon could
be a functional modiﬁer for the development of ESCC [91].
3.2. LncRNAs involved in EAC
EAC is more common in Western and developed countries. The well-
known risk factors include gastroesophageal reﬂux, Barrett's esophagus
(via metaplasia-dysplasia-neoplasia sequence), obesity, caucasian race,
increasing age, alcohol and smoking. The study of lncRNAs in EAC is
not too advanced [92].
In 2013, Wu et al. investigated the role of lncRNA AFAP1-AS1
(Actin Filament Associated Protein 1 – antisense RNA 1) in Barrett's
esophagus (BE) and in EAC. This lncRNA is aberrantly hypomethylated
in the precursor lesion (BE), compared to normal esophageal and gas-
tric tissues. This epigenetic modiﬁcation occurs near the AFAP1-AS1
transcription start site and introgenic regions. Furthermore, this aber-
rant form of lncRNA AFAP1-AS1 has been found to be higher in EAC
than in normal tissues. These results were consistent with its level of
hypomethylation. These data have no eﬀect on the expression of pro-
tein-coding gene AFAP1, a modulator of actin ﬁlament integrity. They
also tested the eﬀects of inhibition of AFAP1-ASA1 in EAC cell lines. Its
silencing reduces cells proliferation and invasion, underlying its onco-
genic role in vitro [93].
LncRNA HNF1A-AS1: Hepatocyte nuclear factor 1 alpha - antisense
RNA 1 is a bidirectional lncrNA. It was found upregulated in human
EAC and its silencing reduced cell proliferation, migration, invasion and
anchorage-independent growth, induces cell cycle arrest and decreases
the expression of H19 [27,94,95]. However, how HNF1A-AS1 regulates
other lncRNAs is required to be further investigated.
In 2014, Wang et al. present their work about advanced GCAs and
lncRNAs/mRNAs aberrant expression. An average of 2300 lncRNAs and
1700 mRNAs were over-expressed. Particularly, ASHG19A3A028863
and ASHG19A3A031505 were the most up-regulated lncRNA and
mRNA, respectively, compared with adjacent non-cancerous tissues.
However, this work is only focused on lncRNAs role in GCA carcino-
genesis [96].
4. LNCRNAs in gastric cancer
GC is the ﬁfth most common malignancies and one of the leading
causes of cancer-related death worldwide. GC is the commonest cancer
in China. From the histological viewpoint, most GC are adenocarci-
nomas. Their pathogenesis is based on the step-by-step pathway (i.e.
Correa's Cascade) due to risk factors, genetic and epigenetic changes.
Recent studies have investigated and focused on the importance of
lncRNAs in this type of cancer. Table 2 summarized and integrate these
studies.
4.1. Upregulated lncRNAs
− MALAT-1, is one of most studied lncRNA because of his pivotal role
in diﬀerent types of cancer; we have extensively talked about this
lcnRNA in the ESCC section, here we add more information about its
potential acting mechanism in GC pathogenesis. Diﬀerent studies
demonstrate that MALAT-1 acts as an oncogene in GC; in fact, its
depletion inhibits cell proliferation, cell cycle, cell migration, and
promotes apoptosis. Recently Xia et al. investigate the relationship
between MALAT-1 and miRNA-122, discovering how miR-122
modulates the MALAT-1 expression in a negative way. Its levels
result higher in GC tissues and in distant metastasis, than those in
normal tissues. MALAT1 is also detectable in plasma and its high
concentration are consistent with the tissue data. Particularly, pa-
tients without distant metastasis show lower plasmatic levels than
patients with distant metastasis, though authors hadn't found any
diﬀerence between patients with GC without metastasis and healthy
controls [97,98]. Wang et al. proved that MALAT1 regulates alter-
native splicing by interaction with the serine/arginine-rich family of
nuclear phosphoproteins [25,99–101]. SF2/ASF is an important
member of this family and it is involved in multiple human cancers
[101]. Authors demonstrated that an in vitro downregulation of SF2/
ASF or MALAT1 provoked cell cycle arrest in G0/G1 phase. These
ﬁndings indicate that MALAT1 may stimulate proliferation of GC
cells partly through mediating SF2/ASF [102]. All these evidences
demonstrate that MALAT1 is a critical promoter in GC cells and
might be an oncogene in human GC.
− HOTAIR: In GC, HOTAIR shows elevated levels in GC cell lines and
tissues compared to normal gastric ones. Lymphovascular invasion,
lymph node metastasis and TNM stages and lower OS rate are linked
to the HOTAIR overexpression in vitro and in vivo [103–105]. Ex-
periments of knockdown HOTAIR expression in cancer cell lines
show: (i) inhibition of cell proliferation in G0-G1 phase through a
cooperative expression and action between HOTAIR and SUZ12 (a
member of PRC2) which could aﬀect the epigenetic status of cancer-
associated genes [104]; (ii) reduction of invasiveness and motility,
through the regulation of metalloproteinase (MMP) 1 and 3 [68];
(iii)reversion the EMT trough miR34a-mediated SNAIL expression
inhibition [106]; (iv) ﬁnally, reveal its role in apoptotic pathway,
since it can activate cleaved PARP-1, an enzyme involved in DNA
repair. In addition, HOTAIR could promote metastasis through
suppression of Poly(rC)-Binding Protein 1 (PCBP1) [107] and is also
involved in HER2 overexpression [106]. HER2 is an oncogene and
its overexpression is associated with poor OS [108]. HER2 is
downregulated by miR-331-3p. In this pathway HOTAIR can act as
ceRNA (a sort of endogenous sponge) that directly bind to miR-331-
3p, thus abolishing the miRNA-induced repressing activity on the
HER2 3′-UTR. Finally, a recent study investigates the eﬀect of HO-
TAIR on patients receiving chemotherapy (ﬂuorouracil and pla-
tinum) and its overexpression is correlated to advanced stages, poor
median survival time and chemo-resistance [109]. All these results
underline the oncogenic role of HOTAIR in GC and highlight his
potential role as a potential predictive biomarker and a novel target
for HER2 positive patients.
− H19 gene is located on locus 11p15.5, near the insulin-like growth
factor 2 (IGF2) gene; it codes for a 2300 bp lncRNA and is highly
expressed during embryogenesis, but its expression is reduced after
birth [110–113]. This gene is only expressed from the maternally-
inherited chromosome, whereas IGF2 is only expressed from the
paternally-inherited chromosome; both are regulated by the diﬀer-
entially methylated region (DMR) or the imprinting control region
(ICR) located 4 kb upstream of the H19 gene [114]. Dysregulation of
H19 expression is observed in many types of cancer, including
esophageal, liver, cervical, bladder, lung, and breast cancer
[94,115–119]; however, H19 could play diﬀerent roles depending
on the tissue type. Indeed, in some tumors, it can act as a tumor
suppressor gene [95,120], but more often, possesses oncogenic
ability [43,121–123]. In GC H19 was shown to be upregulated re-
lative to normal adjacent tissues, as well as in human GC cell lines
compared to the normal gastric epithelial cell lines [18,124–127].
H19 overexpression induces GC cells proliferation and inhibits
apoptosis by partly inactivating p53 and suppressing the expression
of the B-cell lymphoma-associated X protein (BAX), a p53 target.
H19 expression is induced by c-Myc, another oncogene, which reg-
ulates itself GC cells proliferation [123,128]. Furthermore, H19 is
the precursor of miR-675-5p [124]. Both are overexpressed in GC
tissue and miR-675-5p promotes cell proliferation in vitro and in
vivo. MiR-675 targets are Runt domain transcription factor1
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(RUNX1) and Calneuron 1 (CALN1), two tumor suppressor genes,
which are both downregulated in GC. In addition, H19 regulates
directly isthmin (ISM)1, a factor promoting endothelial cell survival
[63,129,130]. Finally, H19 in GC can act also as ceRNAs with miR-
141. In fact, H19 and miR-141 levels are inversely correlated in GC.
In this way H19 can modulate the expression of target genes like
IGF-2, IGF Receptor 1 (IGFR1), and Zinc ﬁnger E-box-Binding
homeobox 1 (ZEB1) [131]. It denotes how, through diﬀerent me-
chanisms, H19 can modulate the expression of multiple genes,
promoting cellular proliferation, invasion and migration [129].
From a clinical point of view H19 over-expression is correlated with
poor prognosis and to a shorter survival time of GC patients
[128,129]. H19 plasma levels observed to be higher in GC patients
than in healthy controls, and conversely postoperative plasma level
is decreased compared to the preoperative ones [132,133]. There-
fore, H19 could be a good and reliable biological marker that can be
used as prognosis predictor and in follow-up serological exams.
− PVT1 (Plasmacytoma variant translocation 1 lncRNA) has been
mapped to 8q24 and its copy-number ampliﬁcation is one of the
most frequent events in a wide variety of cancers, including GC
[134–138]. It seems to have diﬀerent acting mechanisms. Xu and
colleagues demonstrated that the PVT1 promoter contains a binding
site for the transcriptional factor Forkhead Box M1 (FOXM1). PVT1
bind to FOXM1 protein to increase its stabilization, inhibit its ubi-
quitin/26s proteasome-mediated degradation. Contrarily, high level
of FOXM1 induces PVT1 overexpression. This positive feedback loop
promotes GC cells proliferation and metastasis [139]. Furthermore,
PVT1 is involved in epigenetic downregulation of p15INK4B and
p16INK4A through EZH2, promoting GC cells proliferation [139].
Finally, Huang et al. [140] have demonstrated that PVT1 can
“sponging” miR-186 and in this way can reduce the inhibition of
Hypoxia-inducible factor-1α (HIF-1α) expression in GC cells. HIF-1α
is a key transcription factor promoting cancer development and
tumor progression and its overexpression is driven by the in-
tratumoral hypoxia and genetic alterations regarding other onco-
genes and tumor suppressor genes [139,141–143]. In GC, HIF-1α
overexpression correlated with tumor stage and lymph node me-
tastasis, poor OS and DFS in post-gastrectomy patients
[139,144,145]. Thus, these data suggest that PVT1 can act as an
oncogene and the inhibition of HIF-1α could represent a novel ap-
proach to cancer targeted-therapy.
− GAPLINC (Gastric Adenocarcinoma-associated Positive cluster of
diﬀerentiation 44 regulator Long Intergenic Non-Coding RNA) is a
924 bp lncRNA overexpressed in GC and is associated with increased
proliferation and with CD44-dependent oncogenesis, both in vitro
and in vivo [146,147]. CD44, is a well-known oncogene involved in
proliferation, angiogenesis and migration of GC cells [148]. GA-
PLINC is activated by mutant p53 and a strong correlation between
GAPLINC and CD44 expression was reported; noteworthy, CD44
silencing was proved to neutralize oncogenic functions of GAPLINC.
So, Hu et al. [146] showed that GAPLINC can act as a ‘miRNA
sponges’ that prevents CD44-mRNA degradation by competing for
the binding with miRNA 211-3p. In fact, GAPLINC and CD44 are
both negatively modulate by miR-211-3p. In addition, GAPLINC
levels are associated with patients' survival, supporting its role as a
diagnostic and prognostic biomarker for GC patients and as a po-
tential therapeutic target [146].
− GHET1 (Gastric carcinoma High Expressed Transcript 1) which is
located in an intergenic region on chromosome 7 in the locus
7q36.1. By primary screen of aberrantly expressed lncRNAs in GC
Yang et al. showed that GHET1 is signiﬁcantly overexpressed in GC
patients tissue compared to healthy controls. Gain-of-function ex-
periments have demonstrated that overexpression of GHET1 pro-
motes the proliferation of GC cells, while knockdown of GHET1
inhibits the proliferation of GC cells [149,150]. From the molecular
point of view, GHET1 could bind to insulin-like growth factor 2
mRNA binding protein 1 (IGF2BP1) enhancing the physical inter-
action between c-Myc mRNA and IGF2BP1 and consequently in-
creasing the stability of c-Myc mRNA and its protein translation.
Finally, c-Myc overexpression promotes GC cells proliferation [151].
GHET1 and c-Myc levels in GC tissues are signiﬁcantly correlated
and c-Myc knockdown blocks the oncogenic eﬀects of GHET1 in GC
cell lines [151]. GHET1 overexpression is signiﬁcantly correlated
with tumor size and invasion, as well as patients' outcome [151].
− TINCR (Terminal Diﬀerentiation-Induced ncRNA) is a 3700 bp
lncRNA that controls human epidermal diﬀerentiation. LncRNAs
can regulate genes expression at the post-transcriptional level by
directly interacting with mRNAs. The interaction between mRNA
and the complementary lncRNA, form a dsRNA. Staufen 1 (STAU1)
protein recognizes the dsRNA binding sites and this results in mRNA
degradation. This process is called STAU1-mediated mRNA decay
(SMD) [152,153]. For instance, TINCR, whose expression is modu-
lated by the nuclear transcription factor SP1, interact with Krüppel-
like factor 2 (KLF2) mRNA forming a dsRNA, STAU1 bind to this
complex decreasing KLF2 mRNA stability, inhibiting its protein
translation. The post-transcriptional silencing of KLF2 gene down-
regulates the cell cycle inhibitory genes CDKN1A/P21 and CDKN2B/
P15, promoting cancer cells proliferation, migration, invasion and
tumorigenicity, which are inhibited if TINCR is silenced [153].
− HULC (Highly Upregulated in Liver Cancer) is a lncRNA ﬁrstly
identiﬁed in hepatocellular carcinoma. In further studies, was found
upregulated in other cancers, including pancreatic cancer and GC
[154–156]. HULC may be involved in a switch mechanism between
apoptosis and autophagy in vitro. Apoptosis and autophagy are two
components of programmed cell death and have been associated
with a number of physiological processes, including cancer
[157,158]. However, autophagy has been shown to have a dual role
in cancer progression [158]. Mechanistically, HULC overexpression
increases the ratio between microtubule-associated protein 1 Light
Chain 3-II (LC3-II) and LC3-I; LC3-II is the product of proteolytic
maturation of LC3-I and is the marker for the presence of autop-
hagosomes and the proof of the autophagy activation process. No-
tably, deletion of HULC expression, in the same GC cell line, induces
biochemical (increased expression of E-cadherin, decreased expres-
sion of vimentin, and switching to apoptosis) and morphological
(diﬀerent growth pattern and decreased formation of lamellipodia)
changes that lead to a reversion of EMT. In addition, the expression
levels of HULC correlate with GC lymph node metastasis, distant
metastasis and TNM stages [156].
− HOXA11-AS (Homeobox A11-Antisense non-coding RNA) was found
upregulated in GC and in vitro and in vivo assays revealed its po-
tential modulation role in cell growth, migration, invasion, and
apoptosis. HOXA11-AS can act as a scaﬀold binding EZH2 and his-
tone demethylase LSD1 or DNMT1 in order to epigenetically reduce
KLF2 and PRSS8 expression at the transcriptional level. In addition,
can act as a ceRNA for miR-1297, antagonizing its ability to repress
EZH2 protein translation [159].
− CCAT1 is overexpressed in several GC cell lines [160,161]. Its
knockdown inhibits proliferation by inducing apoptosis and G0/G1
arrest. CCAT1 can modulate the expression of extracellular signal-
regulated kinase (ERK) and p38 mitogen-associated protein kinase
(p38 MAPK) [162]. In addition, has been observed a correlation
between CCAT1 and c-Myc mRNA expression; in fact, c-Myc binds to
CCAT1 promoter inducing its expression [160]. Finally, Mizrahi
et al. have reported that there are no signiﬁcant diﬀerences in
CCAT1 expression between H. pylori-negative and -positive patients,
indicating that CCAT dysregulation is a late event in gastric can-
cerogenic cascade [161].
− MRUL (MDR-Related and Upregulated lncRNA) has been reported to
be signiﬁcantly in vitro overexpressed, and knockdown of MRUL
could induce apoptosis and reduce drug release in the presence of
adriamycin or vincristine; this mechanism may be mediated by the
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regulation of ATP-binding cassette, subfamily B, member 1 (ABCB1)
expression [163].
− FRLnc1: Forkhead box protein M1 (FOXM1) Related LncRNA is
modulated by FOXM1, a well-known and studied oncogene. In vivo
overexpression revealed its role in pulmonary metastasis. In fact,
FRLnc1 can regulate the expression of transforming growth factor
1β (TGF-1β) and Twist promoting cell migration and distant tumor
metastasis [164].
− MALAT2 overexpression in GC tissues is correlated with lymph node
metastasis and tumor stage, as well as with shorter DFS. It can
regulate EMT through an MEK/extracellular signal-regulated kinase-
dependent mechanism [165].
− BANCR (BRAF-activated ncRNA) was ﬁrstly identiﬁed as an onco-
gene in melanoma. Recent studies have also demonstrated that its
levels are higher in GC than in normal adjacent tissue; it can act as a
ceRNA reducing the level of miRNA-9 and consequently increasing
the expression of NF-kβ. Its overexpression is signiﬁcantly asso-
ciated with clinical stage, tumor invasiveness, lymph node and
distant metastasis and with shorter OS in GC patients [166].
− GACAT3 (also known as AC130710) is upregulated in GC, and its
expression levels are associated with tumor size, TNM stage, distant
metastasis, and tissue carcinoembryonic antigen (CEA) expression
level. Shen et al. have demonstrated that as a downstream target of
the IL6/STAT3 signaling, lncRNA GACAT3 promotes GC cells
growth, and according to this ﬁnding, GACAT3 could be an in-
ﬂammatory response gene [167,168].
− LncRNA AK058003 is upregulated by hypoxia and is overexpressed
in GC tissues; its in vitro knockdown suppresses cell migration, in-
vasion, and motility and its in vivo downregulation is linked to a
decrease in the number and size of lung and liver metastatic no-
dules. AK058003 can regulate the expression of Synuclein-γ (SNCG),
a metastasis-related gene, that is upregulated also by hypoxia; in
fact, it is basically an eﬀector of hypoxia-induced GC metastasis,
whereas loss of AK058003 decreases SNCG expression via methy-
lation of its promoter [169].
− GClnc1 (Gastric Cancer–associated lncRNA 1) is signiﬁcantly over-
expressed in GC. GClnc1 binds to WDR5 and KAT2A histone acet-
yltransferase, acting as a scaﬀold for WDR5 and KAT2A complexes,
coordinating their localization and consequently altering GC cells
proliferation, migration and invasion [170].
− LncRNA BC032469 overexpression was positively associated with
hTERT level and signiﬁcantly promotes GC cell proliferation and
metastasis. BC032469 can function as ceRNA directly binding to
miR-1207-5p and reducing its inhibitory eﬀect on hTERT expres-
sion, whose overexpression enhances cancer cell proliferation and
metastasis [150].
− LncRNA LINC00152 (Long Intergenic Non-protein-Coding RNA 152)
is overexpressed in GC tissues [171,172]. Recent studies have de-
monstrated that also plasma and gastric juice levels of LINC00152
are signiﬁcantly higher in GC patients compared with healthy con-
trols, therefore it could be a potential promising noninvasive bio-
marker for GC screening [20,171]. However, the function of
LINC00152 in GC should be further investigated.
− As for ESCC lncRNAs UCA1 and ANRIL are involved in GC carci-
nogenetic process and acting in a similar manner (see ESCC section).
In addition, UCA1 levels in gastric juice are higher in GC patients
than in normal individuals, so UCA1 may represent a powerful
prognostic marker [63,173] while ANRIL overexpression is sig-
niﬁcantly correlated with a higher TNM stage, tumor size and
shorter OS time [174].
− HIF1A-AS2 (HIF1A Antisense RNA 2), SUMO1P3 (Small ubiquitin-
like modiﬁer 1 pseudogene 3), ABHD11-AS1 (Abhydrolase Domain
Containing 11- Antisense transcript 1), UBC1 (E2 ubiquitin-con-
jugated protein 1), LSINCT-5 (Long stress-induced noncoding tran-
script 5) and RP11-119F7.4 are overexpressed in GC and most of
them are signiﬁcantly correlated with poor prognosis, tumor size,
lymph node metastasis, diﬀerentiation and TNM stage
[144,165,175,176]; however further investigation are needed to
deeply elucidate their molecular mechanism.
4.2. Downregulated lncRNAs
− GAS5 (Growth Arrest-Speciﬁc transcript 5) is an approximately 650
bp lncRNA and was ﬁrst found among a screen for potential tumor
suppressor genes with high expression during cancer cells growth
arrest [177]. GAS5 was identiﬁed downregulated in various cancer
types such as breast, prostate cancer and GC [178–180]. Its over-
expression inhibits cell proliferation and promotes caspase-3-de-
pendent apoptosis in vivo and in vitro, conversely knockdown of
GAS5 is associated with larger tumor size, advanced pathologic
stage, poorer DFS and OS [181,181]. GAS5 downregulation results
in overexpression of E2F1 and cyclin D1, which induces tumor-
igenesis by stimulating cell proliferation and repressing p21 ex-
pression, an inhibitory modulator of the cell cycle [181,182]. These
data suggest that GAS5 may act as a tumor suppressor through the
post-transcriptional regulation of E2F1 and p21.
− MEG3 (Maternally Expressed Gene 3) is an imprinted gene on
human chromosome 14q32.3 that encodes for a lncRNA [183].
MEG3 downregulation occurring in multiple cancers such as glioma,
bladder cancer, and tongue squamous cell carcinoma [184–186]. In
GC, MEG3 expression is signiﬁcantly downregulated than in ad-
jacent normal tissue, and its downregulation correlates with higher
TNM stage, deeper invasion and larger tumor size. MEG3 acts as a
tumor suppressor inducing G2/M cell cycle arrest and promoting
apoptosis through the activation of p53 [187,188]. MEG3 is epi-
genetically modulated by miR-148a that downregulate DNA me-
thyltransferase-1 and consequently reduce the methylation status of
the MEG3 regulatory regions (MEG3-DMRs) [189,190]. MEG3 can
also act as a ceRNA by competitively binding miR-181a to regulate
Bcl-2 and inhibit cell proliferation [191]. In addition, MEG3 is po-
sitively correlated with miR-141 and inversely correlated with E2F3
[192] regulating cell proliferation, cell diﬀerentiation, and angio-
genesis by interacting with Notch, Rb, VEGF, and growth diﬀer-
entiation factor 15 (GDF15) [183].
− FER1L4 (FER-1-Like protein 4) is a newly identiﬁed lncRNA and it is
signiﬁcantly down-regulated in GC tissues [193]; low expression
levels of FER1L4 are associated with histological grade, tumor size,
TNM stage, lymphatic metastasis, perineural invasion, venous in-
vasion, and CA724 serum levels. Furthermore, its plasma level de-
clines, two weeks after surgery, suggesting that FER1L4 might serve
as a biomarker for biochemical evaluations after surgery [194]. In
addition, more recent studies suggested that FER1L4 could also act
as ceRNA. In fact, FER1L4 levels are correlated with those of PTEN
mRNA; both of these tumor suppressor genes are negatively
modulated by miR-106a-5p, a well-known onco-miRNA; FER1L4 in
vitro downregulation frees miR-106a-5p decreasing the levels of
PTEN mRNA and protein. More importantly, FER1L4 down-
regulation accelerates cell proliferation by promoting the G0/G1 to
S phase transition [195]. However, the mechanism and function of
FER1L4 should be further explored.
− FENDRR (FOXF1 adjacent Non-coding Developmental Regulatory
RNA) is an antisense transcript of 1250 bp located on chromosome
16q24.1, plays an important role in mouse embryogenesis. FENDRR
modulates chromatin remodeling by binding to both PRC2 and
Trithorax group/Mixed lineage leukemia complexes (TrxG/MLL)
[196]. FENDRR is downregulated in GC and its low levels are ne-
gatively correlated with ﬁbronectin (FN)1 and MMP2/MMP9 ex-
pression indicating that FENDRR is a mediator of cell diﬀerentia-
tion, growth, and migration and of GC progression and metastasis
[197]. FENDRR expression level is signiﬁcantly correlated with
tumor stage, lymphatic metastasis and OS and DFS of GC patients
[197].
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− BM742401 is downregulated in GC and its overexpression inhibits
the migration and invasion in vitro, while in vivo suppresses metas-
tasis decreasing the secretion of extracellular MMP9 [198].
− GACAT2 (Gastric cancer-associated transcript 2, also known as
HMlincRNA717), is downregulated in GC in vivo and in vitro. Its
expression was found to be associated with distant metastasis and
venous and perineural invasion. GACAT2 is also downregulated in
gastric precancerous lesions, suggesting its pivotal role during early
stage of GC [168,199].
− PTENP1 (Phosphatase and TENsin homolog - Pseudogene 1) in-
creases PTEN expression by binding to miRNAs (miR-106b and miR-
93) reducing their negative modulation of PTEN expression
[200,201].
− GACAT1 (Gastric cancer-associated transcript 1, also known as
AC096655.1–002), ncRuPAR (Non-Coding RNA, Upstream protease-
activated receptor-1(PAR1)), ZMAT1 transcript variant 2 (Zinc
Finger Matrin-Type 1 transcript variant 2), LET (Low Expression in
Tumor), AI364715 and AC138128.1 have been shown to be down-
regulated in GC and most of them signiﬁcantly correlate with OS
tumor invasion, lymph node metastasis, and TNM stage
[165,202–206]; however their molecular mechanisms are still un-
known and further investigation are needed.
4.3. Other GC-related lncRNAs
Some lncRNAs have been shown to be dysregulated in GC but until
now we have only contrasting and partial data about them. For in-
stance: lncRNA SPRY4-IT expression and function in GC remain a
controversial subject. Xie et al. [207] found that SPRY4-IT1 is down-
regulated in GC and represses cell proliferation in vitro and tumor-
igenesis in vivo. However, Peng et al. [208] found that SPRY4-IT1 is
signiﬁcantly overexpressed in GC tissues. This shows how the SPRY4-
IT1 acting mechanisms are still unknown. Another example is LncRNA
AA174084: its levels in the gastric juice of GC patients are higher than
controls (with normal mucosa, gastritis, ulcers or atrophic gastritis).
These levels are associated with tumor size, tumor stage, histological
type, and gastric juice CEA levels. In addition, plasma levels sig-
niﬁcantly decline postoperatively compared with preoperative levels in
GC patients; this reduction is associated with invasion and lymphatic
metastasis, while high postoperative plasma AA174084 levels are
linked to poor prognosis. However, AA174084 expression is lower in
GC tissues than in control and these levels are negatively associated
with age, Borrmann type, and perineural invasion. Hence, despite this
discrepancy (downregulation in GC tissue and high level in gastric juice
GC patients), AA174084 could be a reliable biomarker for early diag-
nosis and for prognosis prediction [209].
5. Discussion
GC and EC are two of the most common and deadly malignancies
worldwide; in particular, they are the ﬁfth and the sixth leading cause
of cancer-related deaths respectively; despite the huge therapeutic im-
provements, their 5-year survival rates are still very poor also due to
delayed diagnosis and the lack of deep understanding of their complex
pathogenesis.
GC and EC are usually classiﬁed into diﬀerent morphological sub-
types according to diﬀerent systems. However, these classiﬁcations are
not able enough to guide clinical management and stratify patients in
reliable diﬀerent prognostic groups.
In recent years the molecular landscape of these cancers has gained
attention, also because it could bring to novel treatment strategies and
to an early stage diagnosis when lesions are too small to be accurately
detected using imaging modalities.
Considering that only 2% of the whole genome generates protein-
coding transcripts is obvious how we have to elucidate and focus on the
complex modulating role of the 98% non-coding genome. In this novel
context take place lncRNAs, deﬁned as transcripts longer than 200
nucleotides with no protein-coding capacity. They play heterogenous
and pivotal roles in main oncogenic processes as cell proliferation, cell
cycle, diﬀerentiation, programmed cell death, EMT, invasion and mi-
gration. LncRNAs can act at various levels exerting diﬀerent functions:
(i) at epigenetic level they can recruit chromatin remodeling complexes
to speciﬁc genomic loci, can cause methylation of speciﬁc genes pro-
moters, silencing their transcription or can cause histone acetylation,
promoting the expression of targeted genes; (ii) at transcriptional level
they can regulate transcription factors activity; (iii) at post-transcrip-
tional level they can modulate pre-mRNAs splicing process, can func-
tion as a ceRNA interfering with miRNAs-mediated genes expression,
can interfere in post-translational proteins modiﬁcation, or can act as
molecular scaﬀolds participating as a structural component in the as-
sembling of multimeric molecular complexes; (iv) in addition, they can
generate endogenous small interfering RNAs, which are small single- or
double-stranded RNAs that bind to speciﬁc target RNAs facilitating
their degradation; (v) otherwise some lncRNAs can generate small
RNAs, such as miRNAs, piRNAs, or other less characterized small RNAs;
(vi) ﬁnally, SNPs in lncRNA can modify the basal risk to develop ma-
lignancies as for most genes involved in tumorigenesis.
5.1. LncRNAs’ clinical relevance
To date, a large number of lncRNAs have been identiﬁed and
growing eﬀorts have been made in studying their biological functions in
diﬀerent human cancers. However, many key questions remain un-
solved. In fact, in contrast to mRNAs and proteins, their function cannot
simply be described according to their structure or sequence because of
their complex interacting network and diversity. However, from a sta-
tistical viewpoint growing evidences suggest that lncRNAs dysregula-
tion correlates with main oncogenic processes (invasiveness, lymphatic
and distant metastasis, diﬀerentiation) as well as with overall and
disease-free survivals.
Therefore, lncRNAs could represent prognostic and diagnostic bio-
markers. Indeed, lncRNAs: (i) have a quite restricted tissue-speciﬁc
expression, therefore they have a high speciﬁcity; (ii) play a key role in
the initiation, development, and progression of cancer and their ex-
pression levels diﬀer during the diﬀerent stages, so could be of value to
distinguish among patients with cancer in a very early stage (still not
detectable using imaging modalities) from healthy individuals; (iii)
aberrant expression of cancer-speciﬁc lncRNAs can be detected also in
body ﬂuids, including plasma or serum, gastric juice, saliva, cere-
brospinal/peritoneal/pleural ﬂuid and urine, so it is a noninvasive as-
sessment and could be repeated at diﬀerent time points; (iv) it is also
possible to combine several lncRNAs expression levels (or lncRNAs le-
vels with other transcripts levels or with other biomarkers) in order to
obtain a reliable molecular signature that could have a diagnostic and
prognostic value. For instance, Dong et al. found that among 39 cancer-
related lncRNAs UCA1, LSINCT-5 and PTENP1 are the most sig-
niﬁcantly downregulated lncRNAs in GC patients compared with the
control group; therefore, the assessment of their combination is enough
sensitive and speciﬁc to distinguish benign peptic ulcers from GC pa-
tients and lower expression level is linked to worse survival rates
[20,210].
There is also a downside. In fact, we have to better understand how
lncRNAs are released into body ﬂuids because circulating lncRNAs is
unstable in presence of high amount of RNase in peripheral blood, so
they may be packaged into various types of extracellular vesicles (EVs)
or could be modiﬁed (methylation, adenylation and uridylation) to
prevent RNase digestion.
EVs are categorized according their size and origins as: (i) exosomes
(small bilayered EVs with 30–100 nm diameter derived from in-
tracellular budding from multivesicular bodies which are formed by
endosomes membrane) [211]; (ii) microvesicles (100–1000 nm directly
shed from the cellular plasma membrane); (iii) apoptotic bodies
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(500–4000 nm vesicles derived from cell lysis during the late stages of
programmed cell death) [212,213]. EVs can contain: lipids (in their
membranes), proteins, coding and non-coding RNAs and DNA frag-
ments [211] coming from neoplastic cells o virus-infected cells [214].
In cancer progression EVs role is crucial; in fact they could act as in-
tercellular communicative vectors facilitating the carcinogenetic and
the metastatic processes by transferring these key biological molecules;
indeed, in this way also the microenvironment can be modiﬁed in order
to prepare the dissemination [215].
The mechanism underlying lncRNAs secretion has not been deeply
elucidated as for miRNAs but could be very similar, namely through
tetraspanins-positive (CD9, CD63,CD81,CD82) exosomes via a cer-
amide-dependent pathway but without ESCRT (endosomal sorting
complexes required for transport) machinery [216].
In recent studies, circulating lncRNAs with a strong clinico-patho-
logical valence have been detected in exosomes both in GC patients
(LINC00152, ZFAS1) [20,217–219] and in ESCC ones (PART1) [220].
ZFAS1 overexpression has been found in GC cell lines, tumor tissues,
serum and serum exosomes of GC patients and its levels are related to
lymphatic metastasis and TNM stage. Moreover, in vitro has been
proved that ZFAS1, transmitted through exosomes, could enhance the
proliferation and migration of GC cells [219].
Whereas PART1 overexpression promotes geﬁtinib resistance by
regulating miR-129/Bcl-2 pathway in ESCC patients [220].
However, this is only the starting point, further studies are needed
to better elucidate the biological roles of this intercellular interaction
and lots of technical problems have to be solved before the routinely
use of EVs content as reliable biomarker.
Another important challenge could be the use of the ampliﬁcation to
resolve the measurement of lncRNAs low levels in body ﬂuids. To date,
to quantify gene expression is widely used qRT-PCR but for lncRNAs
selecting the appropriate reference genes is extremely critical but is
essential to minimize inter-procedure bias and implement quality con-
trol in clinical laboratories. Finally, we have to take in account that EC
and GC are heterogeneous diseases that encompass diﬀerent histologic
subtypes with diﬀerent and often overlapped risk factors, diﬀerent
therapy strategies as well as diﬀerent prognosis; therefore, despite the
lncRNAs tissue-speciﬁcity, is necessary to correlate their expression
levels with all these important variables.
Hence, large cohort studies are still needed to conﬁrm diagnostic
and prognostic sensitivity and speciﬁcity of certain lncRNAs in gas-
troesophageal malignancies.
5.2. Future perspectives
Apart from being biomarkers, lncRNAs may also provide important
insights for novel targets therapy; they have tissue- and cancer-speciﬁc
expression so could be the ideal therapeutic agents.
Recently high-throughput sequencing technologies are even more
elucidating the complex interaction network between lncRNAs, DNA,
miRNAs, mRNAs and proteins providing novel possible target treat-
ments. At present, siRNAs, antisense oligonucleotides, miRNAs as well
as ribozymes or deoxyribozymes, can be designed to silence en-
dogenous lncRNAs. Conversely, synthetically modiﬁed lncRNA mimics
or plasmid delivery may be used to bring beneﬁcial lncRNAs in vivo.
However, there are still unsolved technical barriers including re-
lative large size, complex secondary structure and possible degradation
by nucleases; these problems could aﬀect design, synthesis and delivery
of functional therapeutic agents to targeted sites. Furthermore, given
the complex and poorly understood interaction networks between
lncRNA and other genes, silencing any lncRNA might have unknown
physiological responses.
Although lncRNA-based therapeutic drugs are still in preclinical
studies, their use seems very promising.
6. Conclusions
In summary, the future of the cancer research will be focused on the
non-coding fraction of the genome. Although we are still trying to
elucidate the complex network that links together lncRNAs, miRNAs,
other non-coding transcripts, mRNAs, proteins and DNA the current
ﬁndings have shown how we are on the right path; indeed, lncRNAs
could ﬁrstly represent reliable biomarkers (sensible, signiﬁcant, early)
and in a next future a possible target for developing new therapies.
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